In addition, recent research has demonstrated the significant therapeutic benefits of combining PD-1 and cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors in the treatment of advanced gastric cancer (16). This evidence concerns the gene PDCD1 and gastric cancer.